BRANMOOR
THURSDAY ยท 14 MAY 2026

FDA Recall D-0507-2026

Wells Pharma of Houston LLC · Houston, TX

Class II Ongoing 43 days on record

Moderate impact — Class II recall โ€” temporary or medically reversible adverse health consequence possible; remote probability of serious adverse health consequence.

Product

Ketamine Hydrochloride Injectable Solution, 50mg/ml, (50 mg per mL) Volume: 1 mL, 5265 Kitty Drive, Houston, TX 77054, NDC 73702-302-31.

Lot / code: 120925302312764, Exp Date 04/09/2026, 123125302312879 Exp Date, 05/05/2026, 123125302312880, Exp Date 05/05/2026, 010226302310003, Exp Date 05/06/2026, 010626302310007, Exp Date 05/08/2026, 010626302310008, Exp Date 05/08/2026 020426302310243, Exp Date 06/06/2026.

Quantity: 4975 syringes

Reason for recall

cGMP deviations.

Recall record

Recall number
D-0507-2026
Classification
Class II
Status
Ongoing
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Letter
Distribution
U.S. Nationwide.
Recall initiated
2026-04-01
Classified by FDA Center
2026-04-28
FDA published
2026-05-06
Recalling firm
Wells Pharma of Houston LLC
Firm location
Houston, TX

Operational response

Class II recalls indicate possible temporary or reversible health consequences. Remove affected lots from active dispensing. Segregate inventory. Check the firm’s recall notification for guidance on patient outreach.

For the official FDA enforcement record, see FDA's Recall Search.

‹ All recalls